The influence of paediatric HIV infection on circulating B cell subsets and CXCR5+ T helper cells by Bamford, A et al.
The influence of paediatric HIV infection on circulating B cell subsets
and CXCR51 T helper cells
A. Bamford,* M. Hart,† H. Lyall,‡
D. Goldblatt,§ P. Kelleher†1
and B. Kampmann*¶1
*Section of Paediatrics, Division of Infectious
Diseases, †Section of Immunology, Division of
Infectious Diseases, Imperial College,
‡Department of Paediatric Infectious Diseases,
Imperial College Healthcare NHS Trust,
§Immunobiology Unit, Institute of Child
Health, University College London, London,
UK, and ¶MRC Unit, The Gambia Vaccinology
Theme, Fajara, The Gambia, West Africa
Accepted for publication 26 February 2015
Correspondence: A. Bamford, Department of
Paediatrics, 2nd Floor Wright-Fleming
Building, St Mary’s Campus, Imperial College
London, Norfolk Place, London W2 1NY,
UK.
E-mail: a.bamford@imperial.ac.uk
1These authors contributed equally to this
study.
Summary
Antiretroviral therapy (ART) only partially restores HIV-induced
alterations in lymphocyte populations. We assessed B and T cell
phenotypes in a cohort of children from a single centre in the United
Kingdom with perinatally acquired HIV compared to healthy controls.
The majority of HIV infected children (44 of 56) were on fully
suppressive combination ART. Children with perinatally acquired HIV
had significantly lower memory B and CD41CD45RO1CXCR51
[follicular T helper cell (Tfh)-like] T cell percentages. Detectable viraemia
was associated with higher CD21– (activated and exhausted/tissue-like
memory) B cells. A greater proportion of life spent on suppressive ART
was associated with higher memory B cell percentages. These results
suggest that early and sustained suppressive ART may preserve B and T
cell phenotypes in perinatally acquired HIV and limit deficits in humoral
immunity. A lower proportion of circulating Tfh-like cells in HIV infected
children appears to be independent of HIV treatment history and ongoing
HIV viraemia and warrants further investigation.
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Introduction
Typically perceived as causing an immune defect affecting
T cells, there are an expanding number of reports describ-
ing B cell phenotype in the context of perinatally
acquired HIV. It is now clear that HIV infection is associ-
ated with phenotypical abnormalities of B cells both on
and off antiretroviral therapy (ART). How ART treatment
history impacts upon potential for B cell immune preser-
vation/reconstitution in perinatally acquired HIV has
evolved more recently as a topic of interest in children
[1–4].
More is known about B cell phenotypical changes in
HIV-infected adults. Observed abnormalities can be par-
tially reversed by ART, while earlier initiation of ART can
result in the preservation of B cell phenotype and function
(reviewed in [5]). There are, of course, important differen-
ces in the immunological characteristics of perinatally
acquired HIV, and adult infection and caution must be
taken when extrapolating from adult data to paediatric
populations: perinatally acquired HIV results in an insult
to a naive and still-developing immune system, which is
reflected in differences in the dynamics of viral replication,
immunosuppression, clinical progression and response to
ART [6].
There is a paucity of data concerning circulating
CD41CD45RO1CXCR51 (follicular T helper (Tfh)-like)
cells in children and no published studies in perinatally
acquired HIV. Debate continues regarding how best to
define Tfh-like cells and how they relate to germinal centre
Tfh. The heterogeneity of studies relating to cell surface
markers, cytokines analysed and cell co-culture methods
have so far limited our understanding of how this subset
may be best characterized, together with their developmen-
tal stage in relation to antigen exposure. However, current
evidence suggests that circulating Tfh-like cells are linked
closely to Tfh, already known to be key players in the B cell
response to T-dependent antigens and resultant B cell dif-
ferentiation [5,7–9]. The importance of Tfh in HIV infec-
tion is increasingly acknowledged. Tfh populations have
been shown to be particularly susceptible to HIV infection
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and are expanded in secondary lymphoid tissue in non-
human primates with simian immunodeficiency virus
(SIV) infection and in humans with chronic HIV infection.
Furthermore, this correlates with expansion of germinal
centre B cell populations. ART is associated with partial
normalization of these observed differences (reviewed in
[5] and [7]).
The aims of this study were to determine the influence
of paediatric HIV infection on circulating Tfh-like cells
and to assess if there was an association between Tfh-like
cells and memory B cell subsets. By assessing the relation-
ship between cell phenotype and current and past ART
status, we highlight the potential for early and sustained
ART to preserve normal lymphocyte (Tfh/B cell)
development.
Methods
Children with perinatally acquired HIV (HIV1) and
healthy, HIV uninfected children (HIV2) aged 2 months–
18 years were recruited from the HIV family clinic and
preoperative assessment clinics at Imperial College
Healthcare NHS Trust, St Mary’s Hospital, London
(August 2009–October 2012). All eligible HIV1 children
were approached. Those consenting to take part in the
study were included. Ethical approval was obtained from
Riverside Research Ethics Committee, Charing Cross
Hospital, London (reference: 09/H0706/23). The parents
of children included in the study provided written
informed consent and human experimentation guidelines
for Imperial College London were followed. Background
demographic and clinical information were obtained
from clinical notes, general practitioner, hospital pathol-
ogy and personal child health records. Exclusion criteria
included ongoing febrile illness, pregnancy, additional
cause of immunosuppression, co-infection with tubercu-
losis, hepatitis B, hepatitis C and HIV-related malignancy.
Ongoing HIV viraemia in the context of known resist-
ance to current anti-retroviral regimen was not an exclu-
sion criterion.
HIV viral load (VL) was measured using branched-chain
DNA assay (Siemens Healthcare, Erlangen, Germany)
[lower limit of detection 50 copies/ml (c/ml)]. Lymphocyte
subsets (LSS) were measured by staining whole blood [eth-
ylenediamine tetraacetic acid (EDTA)] with monoclonal
antibodies [CD45-fluorescein isothiocyanate (FITC), CD4-
RD1, CD8-phycoerythrin-Texas red (ECD), CD3-PC5,
CD56-RD1, CD19-ECD, CD16-phycoerythrin (PE) (Beck-
man Coulter, Brea, CA, USA] and evaluating using FC500
flow cytometer (Beckman Coulter). T and B cell subsets
were identified from whole blood using six-colour flow
cytometry: CD31CD41CD45RO1 (memory T), CD31
CD41CD45RO1CXCR51 (Tfh-like), CD31CD41
CD45RO1CXCR51 inducible T cell co-stimulator
(ICOS)1 (ICOS1Tfh-like), CD191CD101CD21loCD272
(transitional B), CD191CD102immunoglobulin (Ig) D2
CD2711 (plasmablasts), CD191CD102CD272IgD1 (naive
B), CD191CD102CD271IgD1 (IgD1 memory B), CD191
CD102CD271IgD– (class-switched memory B), CD191
CD102CD272IgD2 (double-negative B), CD191CD10–
CD27–CD211 (naive mature B), CD191CD10–CD271
CD211 (resting memory B), CD191CD102CD271CD212
(activated memory B), CD191CD102CD272CD212
(exhausted/tissue-like memory B). Subsets were quantified
by staining with live/dead amine reactive dye (Invitrogen,
Carlsbad, CA, USA) and monoclonal antibodies: IgD-
FITC, CD19-PE-cyanin 7 (Cy7) (Beckman Coulter), CD27-
allophyocyanin (APC), CD21-PE, CD3-APC-Cy7 (BD Bio-
sciences, San Jose, CA, USA), CD10-peridinin chlorophyll
(PerCP) (Exbio, Vestec, Czech Republic) for B cell subsets
and CD3-APC-Cy7, CXCR5-Axf647, ICOS-PE, CD45RO-
FITC (BD Biosciences) and CD4-PE-Cy7, CD14-ECD,
CD19-ECD (Beckman Coulter) for T cell subsets. Acquisi-
tion was performed on an LSR II (BD Biosciences). A mini-
mum of 10 000 CD19 events and 30 000 CD4 events were
acquired. Data were analysed using FlowJo software version
9.4 (TreeStar Inc., Ashland, OR, USA). To allow comparison
with currently available literature, gating strategy was guided
by existing reports on memory B cell and Tfh-like cell phe-
notype [10–12] and is shown in Fig. 1a,b.
Analysis was performed using Stata IC version 121 for
Mac (StataCorp, College Station, TX, USA). v2 and Fisher’s
exact test were used to compare proportions and the
Mann–Whitney U-test to compare baseline age and linear
regression was used to compare log-transformed cell subset
data between groups (allowing adjustment for age and to
assess interactions between age and group). Linear regres-
sion was also used to investigate the relationship between
lymphocyte, B and T cell subsets and clinical history and
the association between T and B cell subsets within the
HIV1 group. Clinical variables assessed included viral load
> 50 c/ml (yes/no), ART commenced in the first year of life
(yes/no), ART commenced in the first 2 years of life (yes/
no), nadir CD4% and proportion of life with viral load
< 50 c/ml expressed as a percentage. HIV1 children had
historical data on three to four monthly measures of VL.
The proportion of life with an undetectable VL was esti-
mated assuming that, prior to commencing ART, the VL
was always detectable. A significance level of P< 005 was
considered significant.
Results
Thirty HIV2 and 58 HIV1 children were recruited. The
baseline characteristics are summarized in Table 1. In line
with the study design and target population, there were sig-
nificant differences in ethnicity. HIV2 median age was
lower than HIV1 (1075 months versus 1515 months, P5
0009); 44 of 56 (786%) of HIV1 patients were on ART
with an undetectable VL at the time of blood sampling. Of
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Fig. 1. Gating strategy for identification of (a) B cell subsets and (b) T cell subsets. Following identification of live CD32 cells, CD191 B
lymphocytes were identified by sequentially gating forward-scatter (FSC)-A versus side-scatter (SSC)-A, FSC-A versus FSC-H, CD19 versus SSC-A.
CD101CD272 and CD2711 immunoglobulin (Ig)D2 cells were then quantified. The remaining cells were subdivided in two ways: CD27 versus IgD
and CD27 versus CD21, resulting in eight further subsets. Following identification of live CD192CD142 cells, CD41 T lymphocytes were identified
by sequentially gating FSC-A versus SSC-A, FSC-A versus FSC-H, CD3 versus CD4. Further subsets were identified using CD45RO, CXCR5 and
inducible T cell co-stimulator (ICOS). Typical contour plots from (c) a healthy child and a child with perinatally acquired HIV of approximately the
same age, (d) a child with detectable viral load (VL) and a child with VL < 50 copies/ml. Children with perinatally acquired HIV have higher
percentages of naive B cell subsets (CD272) and a correspondingly lower percentage of memory subsets (CD271) compared to healthy children.
Detectable VL is associated with an over-representation of CD212 populations (CD271CD212 and CD272CD212). (e) Regression plots comparing
healthy children with children with perinatally acquired HIV. Subsets are reported as described for Table 1. When comparing HIV2 with HIV1
groups, significant differences in CD271CD211, CD272IgD1, CD271IgDv, CD271IgD2 and CD45RO1CXCR51 cells were observed after adjusting
for age (P < 005) HIV2 = HIV uninfected child healthy control; HIV1 = HIV-infected child; VL= HIV viral load; ln = natural log.
those with detectable VL, two patients had never started
ART; the remaining children were on structured treatment
interruption or were known to have variable adherence. No
child with detectable VL was on ART with known viral
resistance to their current regimen. All ART-treated chil-
dren were on standard three-drug therapy consisting of a
Table 1. Baseline characteristics plus lymphocyte, T and B cell subset results
HIV2 (n5 30) HIV1 (n5 56)
Sex Female 14 (467) 25 (446)
Male 16 (533) 31 (554)
Ethnicity White 4 (133) 2 (36)
Mixed 0 (0) 3 (54)
Asian 0 (0) 3 (54)
Black Caribbean 4 (133) 2 (36)
Black African 13 (433) 45 (804)*
Other 9 (30) 1 (18)
Age/months 1075 (19–195) 1515† (12–209)
Nadir CD4% – – 13 (0–48)
Proportion of life VL<50 copies/ml – – 047 (0–098)
VL< 50 copies/ml – – 44 (786)
ART commenced in 1st year – – 10 (179)
ART commenced in 1st 2 years – – 15 (268)
Lymphocyte subsets Lymph cells/ll 22503 (18922–26762) 241911‡ (21454–27278)
CD3 cells/ll 16312 (13757–19341) 18394‡ (16324–20728)
CD3% 711 (680–744) 738 (717–758)
CD4 cells/ll 9157 (7753–10815) 7991§ (6748–9463)
CD4% 401 (370–436) 320‡ (290–353)
CD8 cells/ll 5581 (4517–6896) 8496§¶ (7483–9646)
CD8% 245 (227–263) 340‡ (311–371)
CD19 cells/ll 4220 (3239–5497) 3921§ (3294–4668)
CD19% 183 (159–212) 164§ (149–180)
CD56 cells/ll 1111 (807–1529) 109‡ (881–1347)
CD56% 50 (38–65) 44 (36–52)
CD191 B cell subsets
Transitional CD101CD21loCD27–% 120 (086–166) 134 (109–165)
Plasmablasts CD102CD2711IgD2% 088 (066–116) 084 (063–110)
Naive mature CD272CD211% 7183 (6840–7542) 7396 (6991–7825)
Resting memory CD271CD211% 1877 (1595–2209) 1262¶ (1078–1478)
Activated memory CD271CD212% 206 (162–264) 189 (146–246)
Exhausted/tissue-like memory CD272CD212% 376 (299–472) 506 (413–620)
Naive CD272IgD1% 7038 (6655–7444) 7544¶ (7278–7820)
IgD1 memory CD271IgD1% 982 (824–1171) 660¶ (566–768)
Class-switched memory CD271IgD2% 1131 (946–1352) 871¶** (734–1034)
Double negative CD272IgD2% 469 (386–570) 526 (451–612)
CD41 T cell subsets
Memory CD45RO1% 3205 (2838–3620) 3410 (3101–3751)
Tfh- like CD45RO1CXCR51% 2626 (2369–2910) 1736¶ (1393–2164)
ICOS1 Tfh-like CD45RO1CXCR51ICOS1% 075 (053–107 059 (043–082)
Sex, ethnicity, HIV viral load status and highly active retroviral therapy (HAART) commenced in the first year of life, HAART commenced in
the first 2 years of life are presented as number and percentage. Age, nadir CD4% and proportion of life with undetectable viral load are pre-
sented as median and range. Lymphocyte, T and B cell subsets are presented as geometric mean and 95% confidence interval.
CD101CD21loCD272 (transitional B cells) and CD10–CD2711imunoglobulin (Ig)D– (plasmablasts) reported as a proportion of CD191 cells.
Remaining B cell subsets reported as a proportion of CD191 after exclusion of transitional B cells and plasmablasts. CD45RO1 reported as a pro-
portion of CD41. CD45RO1CXCR51 (Tfh-like cells) and CD45RO1CXCR51ICOS1 reported as a proportion of CD41CD45RO1. HIV25
HIV-uninfected child healthy control; HIV15HIV-infected child; VL5HIV viral load; ART5 anti-retroviral therapy; ICOS5 inducible T cell
co-stimulator. *Proportion significantly different: HIV1 versus HIV2 (P< 0005). †Median significantly different from HIV– (P< 005).
< 005). ‡Significant age3 group interaction when comparing HIV– versus HIV1 (P< 005). §Significant independent age effect when com-
paring HIV– versus HIV1 (P< 005). ¶Significant independent group effect when comparing HIV– versus HIV1 (P< 005). **Non-signifi-
cant after adjusting for detectable viraemia (VL> 50 copies/ml) (P> 005).
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non-nucleoside reverse transcriptase inhibitor or a protease
inhibitor plus two nucleoside/nucleotide reverse transcrip-
tase inhibitors. Median VL was 1227 c/ml [interquartile
range (IQR)5 368–14 236] in those with detectable HIV at
the time of blood sampling.
We first compared LSS and B and T cell subsets
between HIV1 and HIV2 children and adolescents (Table
1, Fig. 1e, Supporting information, Figs S1 and S2)
Lymphocyte subsets
There were significant differences in LSS between groups,
the pattern of difference often varying with age (interac-
tion effect). Regression plots for lymphocyte subset num-
ber and percentage in relation to age are shown in the
Supporting information, Fig. S1. There were significant
interactions between patient group and age for lympho-
cyte, CD31, CD41 and CD561 cell counts, and CD8 and
CD4 percentage (P< 005). Lymphocyte and CD31
counts for younger children were higher for HIV1 than
HIV2, but more equivalent in older children. For CD41
count, younger HIV1 children had higher counts than
HIV2 children and older HIV1 children had lower
counts than HIV2. For CD561 count, older children in
the HIV1 group had lower counts than HIV2 children of
a similar age. For CD8%, older HIV1 children had higher
percentages than HIV2 children of a similar age. Con-
versely, older HIV1 children had lower CD4% than
HIV2 children of a similar age. The only subset for which
there was a significant independent group effect after
adjusting for age was CD81 count, with higher CD81
counts in the HIV1 group than in the HIV2 group.
There was a significant independent age effect for CD191
count and percentage (older children having lower counts
and percentage). All effects remained significant after
adjusting for detectable viraemia.
Follicular T helper (Tfh)-like cells
After adjusting for age, CD45RO1CXCR51 (Tfh-like)
percentages were lower in HIV1 than in HIV2 children
(P< 005) (Table 1, Fig. 1e). This remained significant
after correcting for detectable viraemia. There was no dif-
ference in proportions of CD41CD45RO1 T cells or
ICOS1 Tfh-like cells.
B cell subsets
There were significant differences in B cell subset percen-
tages in children with perinatally acquired HIV when
compared to healthy children (Table 1, Fig. 1e). Represen-
tative contour plots for gating CD27 versus CD21 and
CD27 versus IgD are shown in Fig. 1c. Regression plots
for those subsets for which there was a significant differ-
ence between groups are shown in Fig. 1e (for remaining
subsets see Supporting information, Fig. S2a). No signifi-
cant interaction effects were observed. After adjusting for
age, resting memory B cell percentages were lower in
HIV1 than HIV2 (P< 0005). This difference was also
seen in both IgD1 memory (P< 0005) and class-
switched memory B cell subsets (P< 005). Naive B cell
proportions were higher in HIV1 than HIV2 (P< 005).
After adjustment for detectable viraemia (VL> 50 c/ml),
there was no significant difference in class-switched mem-
ory B cells.
We next analysed data from HIV1 children alone to
investigate the relationship between HIV treatment his-
tory and other clinical parameters and lymphocyte, B and
T cell subsets (Supporting information, Table S1).
Lymphocyte subsets
After adjusting for age, detectable viral load was associ-
ated with significantly lower CD41 and CD561 cell
counts (P< 00001 and P5 0.021, respectively) and per-
centages (P< 00001 and P5 0.005, respectively) and
higher CD81 counts (P5 0002) and percentages
(P< 00001). A larger proportion of life with undetect-
able viral load was associated with higher CD41 counts
(P5 0001) and percentages (P< 00001) and lower
CD81 counts (P5 0004) and percentages (P< 00001),
having adjusted for age. After adjusting for detectable
HIV viraemia, only a higher CD4 percentage was associ-
ated significantly with a larger proportion of life spent
with undetectable viral load. HIV treatment in the first
year of life was also found to be associated with higher
CD4 percentage after adjusting for age and detectable vir-
aemia (P5 0007). There was no association of nadir
CD4% or treatment in the first 2 years of life with any
lymphocyte subset after adjusting for age and detectable
viraemia.
Tfh-like cells
After adjusting for age, a larger proportion of life spent
with undetectable viral load was associated with lower
percentages of CD41CD45RO1 T cells (P5 0026). In
addition, treatment commenced in the first year of life
was associated with lower CD41CD45RO1 cell percen-
tages (P5 0016). These associations remained significant
after correcting for detectable viraemia. No association
was found between Tfh-like cells and the clinical variables
assessed, including viral load > 50 c/ml, ART commenced
in the first year of life, ART commenced in the first
2 years of life, nadir CD4% and proportion of life with
viral load < 50 c/ml.
B cell subsets
Alteration in B cell subsets was more pronounced in HIV
viraemic children and were also associated with a larger
proportion of life spent with detectable viral load. After
adjusting for age, children with a detectable VL had
A. Bamford et al.
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higher percentages of activated and exhausted/tissue-like
memory B cells (P5 0003 and P< 00001, respectively)
and correspondingly lower percentages of resting memory
and naive B cells (P5 0001 and P5 0025, respectively).
Lower percentages of class-switched memory (P5 0048)
and higher transitional B cell percentages (P5 003) were
also observed. A larger proportion of life spent with
undetectable viral load was associated with a higher pro-
portion of resting memory, IgD1 memory and class-
switched memory B cells (P< 00001, P5 0014 and P5
0001, respectively). These associations remained signifi-
cant after adjusting for detectable viraemia. Reduced
exhausted/tissue-like memory B cells were also associated
with a larger proportion of life spent with undetectable
VL (P5 0002); however, this was non-significant after
adjusting for detectable viraemia. No association was
found between any B cell subset, treatment commenced
in the first 1 or 2 years of life or nadir CD4%.
Lastly, we investigated the relationship between B and
T cell subsets.
After adjustment for age there were significant positive
associations between CD41 T cell percentage and resting
memory [regression coefficient5 0957, 95% confidence
interval (CI)5 0564–1350, P< 0001], IgD1 memory
(regression coefficient5 0478, 95% CI5 0042–0915,
P5 0.032) and class-switched (regression coefficient5
0791, 95% CI5 0329–1254, P5 0001) memory B cell
percentages. A significant negative association between
CD41 percentage and exhausted/tissue-like (regression
coefficient520903, 95% CI521459–0348, P5 0002)
was also found. After correcting for detectable viraemia,
the association with exhausted/tissue-like memory B cells
was not significant. At any given age a higher CD41 T
cell percentage in children with perinatally acquired HIV
is associated with a higher percentage of resting, IgD1
and class-switched memory B cells. No significant associ-
ation was found between memory T cell, Tfh-like and
ICOS1 Tfh-like and B cell subsets.
Discussion
To our knowledge, this is the first study to report both
circulating B cell subsets and Tfh-like cells in children
with perinatally acquired HIV compared to healthy chil-
dren, adding to existing published data on B cell pheno-
types in HIV-infected children. We have shown
perinatally acquired HIV infection to be associated with
reduced Tfh-like cells and resting memory and IgD1
memory B cells. Detectable viraemia is associated with
reduced resting and class-switched memory B cell percen-
tages and increased activated and exhausted/tissue-like
memory B cell percentages. Alterations in B cell subsets
exist despite suppressive ART; however, a greater propor-
tion of life spent on ART is associated with a more pre-
served B cell phenotype.
Our observed differences in LSS are consistent with
the published data on incomplete immune reconstitution
in ART-treated children. Despite suppressive ART, some
children continue to have lower CD4 counts (reviewed
in [13]) and CD8 cell counts remain elevated even
when VL is undetectable [14]. Our finding that a
greater proportion of life spent on suppressive ART and
ART commencement in the first year of life are associ-
ated with higher CD4 counts/percentages is consistent
with accumulating data that earlier and sustained VL
suppression may be associated with CD4 count preserva-
tion [13,15].
In parallel, we have found perinatally acquired HIV to
be associated with decreased resting memory and IgD1
memory B cell percentages, while a greater proportion of
life spent on suppressive ART is associated with higher
memory B cell percentages. Furthermore, we found a sig-
nificant positive association between CD4 percentage and
resting memory, IgD1 and IgD2 memory B cells. This is
consistent with existing data sugggesting that earlier ART
commencement may also preserve the B cell compart-
ment [2,5,13]. Taken together, our data support recent
changes to guidelines recommending earlier ART initia-
tion at higher CD4 thresholds in childhood [16]. Mecha-
nisms contributing to sustained B cell phenotypical
abnormalities on ART are unclear; however, it is consid-
ered to be due probably to a combination of irreversible
damage to lymphoid tissue architecture and function
(sustained during viraemic periods) and ongoing low-
level immune activation [5]. Double-negative B cells
(CD272IgD2), similar to a population observed in
elderly people, have been shown recently to be increased
in children with chronic HIV infection, a phenomenon
that may be related to ‘immune senescence’. We did not
observe this, due possibly to our cohort being younger or
there being a lower proportion of viraemic patients than
in the published reports [17,18].
Deficiencies in memory B cell populations, at least
those post-germinal centre, could theoretically be related
to the reduction in Tfh-like cells we observed. Lower pro-
portions of dysfunctional circulating CD41CXCR51 pop-
ulations have been reported recently in ART-naive adult
HIV infection, with proportions increasing following ART
initiation [19]. As is the case for our cohort, this may
reflect a true reduction in cell numbers, although recent
work suggests that it is due more probably to a redistrib-
ution of cells within lymphoid tissue [20] (reviewed in
[7]). Again, it is important to note that differences in our
findings and published work to date are likely to exist in
view of the rapidly changing cell dynamics of the child’s
developing immune system compared to adults. Tfh cell
responses to immunization have been shown recently to
be relatively impaired in neonatal mice when compared
Lymphocyte phenotype in paediatric HIV
VC 2015 The Authors Clinical and Experimental Immunology published by John Wiley & Sons Ltd on behalf of British
Society for Immunology, Clinical and Experimental Immunology, 181: 110–117
115
to adult mice [21]. It remains to be shown whether the
same is true in human infants.
Whether or not related, the fact that deficits in both
Tfh-like cells and memory B cells exist in ART-treated
children with perinatally acquired HIV, and that viraemic
children have higher numbers of tissue-like/exhausted
and activated memory B cells, is cause for concern. It has
implications for ART treatment strategies, as earlier and
sustained ART may preserve T and B cell phenotypes, and
for vaccination practices, where serological response may
be optimized by immunizing once established on fully
suppressive ART. This is relevant for both routine immu-
nizations in HIV-infected children and also for therapeu-
tic HIV vaccination as part of a future potential
combined approach to HIV treatment.
Our study is limited by a lack of matching for ethnicity
between the HIV1 and HIV2 groups. This was unavoid-
able, owing to the time available for recruitment and
demographics of the population from which healthy chil-
dren were recruited. Better matching for ethnicity would
have helped to exclude this as a potential confounding
factor. However, at the time of writing we are not aware
of any existing published data reporting variations in
Tfh-like cells or memory B cell populations between eth-
nic groups. Furthermore, the median age of the HIV1
group was higher than that of the HIV2 group. This has
been addressed by adjusting for age during statistical
analysis. The need for this would have been avoided
through precise age-matching at the time of recruitment,
but this was not possible. There have been rapid recent
developments in the phenotypical characterization of
both memory B and Tfh-like cells (summarized in [5]).
The addition of further markers/additional gating strat-
egies and functional analysis of Tfh-like cells, although
adding to the complexity of the data analysis, would have
enhanced our findings and will be the focus of future
work. The implications of the observed abnormalities for
vaccine responses has also been assessed, and is the sub-
ject of a separate paper [22].
In summary, findings from our work and other studies
of human HIV infection and non-human primate SIV
models are indicative of a complex interplay between HIV,
Tfh and B cells in lymphoid tissue and peripheral circula-
tion to the detriment of humoral immunity, which is only
partially corrected by ART. Current evidence suggests there
may be an accumulation of HIV-specific and/or infected
Tfh in lymph nodes, which correlates with the altered
lymph node B cell phenotype. This is reflected in altered T
and B cell phenotypes in the peripheral blood which, in
turn, can be correlated with impaired response to vaccina-
tion [5]. Our results not only emphasize that T and B cell
abnormalities persist in children with HIV despite suppres-
sive ART, but also provide evidence that earlier and sus-
tained ART serves to maximize the potential for normal
immune development beyond its effect on CD41 T cells.
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Fig. S1. Regression plots comparing lymphocyte subsets
in healthy children with children with perinatally acquired
HIV. Significant interactions between age and group were
present for lymphocyte, CD31, CD41 and CD561 cell
counts (P< 005) and for CD41 percentage (P< 0005).
Significant independent age effects were present for
CD81 and CD191 cell counts and CD191 percentage
(P< 0005). Significant independent group effect was
present for CD81 cell count (P< 0005). HIV25HIV-
uninfected child healthy control; HIV15HIV-infected
child; ln5 natural log, cell counts measured in cells/ll.
Fig. S2. Regression plots comparing (a) B cell and (b) T
cell subsets for which there was no significant group
effect when comparing healthy children with children
with perinatally acquired HIV. HIV25HIV=uninfected
child healthy control; HIV15 child patient; ln5 natural
log. Percentages are reported as described in Table 1.
Table S1. Results of separate linear regression analyses for
detectable viral load and proportion of life undetectable
after adjusting for age for HIV group alone.
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